08:05:45 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Optimi Health Corp
Symbol OPTI
Shares Issued 87,038,441
Close 2023-09-06 C$ 0.19
Market Cap C$ 16,537,304
Recent Sedar Documents

Optimi receives licence amendment from Health Canada

2023-09-07 11:15 ET - News Release

Mr. Bill Ciprick reports

OPTIMI HEALTH GRANTED AMENDMENT TO DEALER'S LICENCE BY HEALTH CANADA TO SUPPLY SPECIAL ACCESS PROGRAM

Health Canada has approved an amendment to Optimi Health Corp.'s dealer's licence. The amendment empowers Optimi to embark on the formal supply journey for Canada's special access program (SAP), operating within the provisions of the Controlled Drugs and Substances Act and its regulations.

Under rigorous licensing regulations, Canadian entities engaged in the cultivation and formulation of psychedelic substances, and who wish to supply Canada's special access program, must secure approval from Health Canada's Office of Controlled Substances Division. Optimi has successfully navigated this regulatory landscape, surmounting the initial hurdle required to supply MDMA (3,4-methylenedioxy-N-methamphetamine) and psilocybin drug candidates produced under the company's licence.

Bill Ciprick, chief executive officer of Optimi, is optimistic about the company's path toward SAP supply. "Our consistent dedication over recent months has strengthened our capabilities in GMP [good manufacturing practice]psychedelics production," says Mr. Ciprick. "The hard work during this time ensures that our in-house-formulated drug candidates will be available to health care professionals, addressing the therapeutic needs of their patients."

Karina Lahnakoski, director of quality and commercial strategies at Optimi, emphasizes the paramount importance of accountability in GMP supply. "Safety, scale and quality hold the key to our ability to cater to practitioners within Canada and Australia," Ms. Lahnakoski underscores, reinforcing the company's commitment to impeccable standards.

About Optimi Health Corp.

Optimi Health is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply psychedelic substances such as 3,4-Methylenedioxymethamphetamine and natural, GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the company's goal is to be the No. 1 trusted, compassionate supplier of safe drug products throughout the world. Optimi's products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, B.C.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.